semaglutide + cagrilintide blend Semaglutide + Cagrilintide Blend (Research)

Based on REDEFINE trial populations and the NDA submission terms, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea Adults 18 years or older Not pregnant or breastfeeding Contraindications will likely include: personal or family history of MTC or MEN 2 syndrome, prior serious allergic reaction to semaglutide or cagrilintide, and active pancreatitis

Follow-up Repeat broad markers after 6-12 weeks if symptoms change, inflammation is part of the context, or the protocol continues

It could be due to lifestyle interventions applied to participants but the nocebo effect is also very real

Long-term outcomes The 68-week clinical trial data provides the best window into long-term expectations